Unresectable Stage III NSCLC Should Not be Treated With Neoadjuvant Therapy and Re-Evaluated for Resection-Reference-Cited by-同舟云学术

Unresectable Stage III NSCLC Should Not be Treated With Neoadjuvant Therapy and Re-Evaluated for Resection

Published:2023-09 Issue:9 Volume:18 Page:1129-1133
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Moghanaki Drew^ORCID,Lisberg Aaron,Oh Scott,Lee Jay Moon

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference31 articles.

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small cell lung cancer collaborative group;BMJ,1995

2. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group;Pignon;J Clin Oncol,2008

3. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer;Forde;N Engl J Med,2022

4. Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): interim event-free survival (EFS) analysis of the phase III Neotorch study;Lu;J Clin Oncol,2023

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study;Signal Transduction and Targeted Therapy;2024-06-14

2. The analysis of current international recommendations for the treatment of patients with stage III non-small cell lung cancer;Grekov's Bulletin of Surgery;2024-05-19

3. The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis;JTO Clinical and Research Reports;2024-03